We are live on ! Find out more
SPRB

Spruce Biosciences
SPRB

40 hedge funds and large institutions have $313M invested in Spruce Biosciences in 2021 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 14 increasing their positions, 12 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 12

11% less funds holding

Funds holding: 45 → 40 (-5)

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

32% less capital invested

Capital invested by funds: $459M → $313M (-$146M)

83% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 6

Holders
40
Holders Change
-5
Holders Change %
-11.11%
% of All Funds
0.7%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.07%
New
1
Increased
14
Reduced
12
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Sio Capital Management
New York
+$3.61M
2
Morgan Stanley
Morgan Stanley
New York
+$593K
3
BlackRock
BlackRock
New York
+$272K
4
Goldman Sachs
Goldman Sachs
New York
+$255K
5
Bank of America
Bank of America
North Carolina
+$232K

Top Sellers

Rank Fund Capital Flow
1
RSCM
Rock Springs Capital Management
Maryland
-$1.06M
2
Millennium Management
Millennium Management
New York
-$1.06M
3
AIC
AWM Investment Company
New York
-$972K
4
PHS
PFM Health Sciences
California
-$812K
5
ZP
Zimmer Partners
New York
-$486K
Name Holding Trade Value Shares
Change 		Change in
Stake
NHAS
1
Novo Holdings A/S
Denmark
$82.8M – – –
OFM
2
Omega Fund Management
Massachusetts
$35.9M – – –
RVM
3
RiverVest Venture Management
Missouri
$35.7M – – –
Citadel Advisors
4
Citadel Advisors
Florida
$28.3M +$21.5K +14 +0.1%
RSCM
5
Rock Springs Capital Management
Maryland
$26.2M -$1.06M -690 -3%
ACM
6
Aisling Capital Management
New York
$20M – – –
Fidelity Investments
7
Fidelity Investments
Massachusetts
$19.8M +$16.9K +11 +0.1%
SCM
8
Sio Capital Management
New York
$13.5M +$3.61M +2,349 +28%
Sands Capital Management
9
Sands Capital Management
Virginia
$13.1M – – –
PHS
10
PFM Health Sciences
California
$8.13M -$812K -529 -7%
BlackRock
11
BlackRock
New York
$5.73M +$272K +177 +4%
Adage Capital Partners
12
Adage Capital Partners
Massachusetts
$4.82M – – –
Vanguard Group
13
Vanguard Group
Pennsylvania
$3.13M +$92.1K +60 +2%
JP Morgan Chase
14
JP Morgan Chase
New York
$2.99M -$181K -118 -5%
ACH
15
ArrowMark Colorado Holdings
Colorado
$2.13M – – –
Geode Capital Management
16
Geode Capital Management
Massachusetts
$1.82M -$163K -106 -7%
GPCM
17
Granite Point Capital Management
Massachusetts
$1.66M – – –
State Street
18
State Street
Massachusetts
$1.57M +$138K +90 +8%
Northern Trust
19
Northern Trust
Illinois
$1.26M -$62.9K -41 -4%
Millennium Management
20
Millennium Management
New York
$1.21M -$1.06M -689 -41%
Charles Schwab
21
Charles Schwab
California
$733K +$78.3K +51 +9%
Morgan Stanley
22
Morgan Stanley
New York
$569K +$593K +386 +544%
CS
23
Credit Suisse
Switzerland
$397K -$36.8K -24 -7%
LCM
24
Laurion Capital Management
New York
$332K – – –
Bank of New York Mellon
25
Bank of New York Mellon
New York
$318K +$117K +76 +42%
1
2

SPRB Hedge Fund Activity: Q1 2021 in Review

40 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q1 2021, worth a combined $313M — down 32% from $459M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of SPRB and 1 opened new positions — a net loss of 5 holders — while 12 trimmed existing stakes and 14 added.

The largest buyer was Sio Capital Management, adding an estimated $3.61M. The largest seller was Rock Springs Capital Management, cutting an estimated $1.06M.

  • 40 institutional investors held Spruce Biosciences (SPRB) as of Q1 2021, down from 45 in Q4 2020.
  • Funds reported $313M of Spruce Biosciences stock for Q1 2021, down 32% quarter-over-quarter.
  • 1 fund opened new Spruce Biosciences positions in Q1 2021 and 6 closed out, a net change of -5 holders.
  • The largest Spruce Biosciences buyer in Q1 2021 was Sio Capital Management, an estimated $3.61M added.
  • The largest Spruce Biosciences seller in Q1 2021 was Rock Springs Capital Management, an estimated $1.06M sold.

Based on aggregated 13F filings for Q1 2021.